Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (...

SAN DIEGO, Oct. 11, 2016 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET.  The meeting is taking place October 15-19 in Vienna, Austria.  The data will also be published in the December issue of United European Gastroenterology Journal, a peer-reviewed medical journal providing coverage of both translational as well as clinical studies from all fields of gastroenterology.

The following abstract will be presented:

Lecture: LB20 - RECEPTOR PROFILE AND EFFICACY OF ETRASIMOD (APD334), AN ORAL, NEXT-GENERATION SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR IN DEVELOPMENT FOR ULCERATIVE COLITIS
Session: 807 - Improving therapy in IBD
Session Type: Late Breaking Abstracts
Date: Tuesday, October 18, 2016

About Arena Pharmaceuticals
We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas.  We have three primary proprietary investigational clinical programs: etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis, APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH).  Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; the publication of the data; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc. 
Kevin R. Lind, Chief Financial Officer   
[e-mail]
858.453.7200, ext. 1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-acceptance-of-late-breaking-etrasimod-abstract-at-the-united-european-gastroenterology-week-uegw-meeting-300342129.html

SOURCE Arena Pharmaceuticals, Inc.

Copyright 2016 PR Newswire